Radiolabeled Cetuximab Conjugates for EGFR Targeted Cancer Diagnostics and Therapy

Radiolabeled Cetuximab Conjugates for EGFR Targeted Cancer Diagnostics and Therapy

The epidermal growth factor receptor (EGFR) has evolved over years into a main molecular target for the treatment of different cancer entities. In this regard, the anti-EGFR antibody cetuximab has been approved alone or in combination with: (a) chemotherapy for treatment of colorectal and head and...

Full description

Bibliographic Details
Main Authors:	Wiebke Sihver, Jens Pietzsch, Mechthild Krause, Michael Baumann, Jörg Steinbach, Hans-Jürgen Pietzsch
Format:	Article
Language:	English
Published:	MDPI AG 2014-03-01
Series:	Pharmaceuticals
Subjects:	EGFR radiolabeled cetuximab conjugates radioimmunotherapy (RIT) cancer theranostics external beam radiotherapy (EBRT) endoradionuclide therapy
Online Access:	http://www.mdpi.com/1424-8247/7/3/311

Similar Items

Development of Anti-Yersinia pestis Human Antibodies with Features Required for Diagnostic and Therapeutic Applications
by: Lillo AM, et al.
Published: (2020-11-01)

Cetuximab-Triptolide Conjugate Suppresses the Growth of EGFR-Overexpressing Lung Cancers through Targeting RNA Polymerase II
by: Keqiang Zhang, et al.
Published: (2020-09-01)

Lutetium 177-Labeled Cetuximab Evaluation for Radioimmunotherapeutic Applications
by: Kamal Yavari, et al.
Published: (2012-06-01)

Radiolabeled theranostics: magnetic and gold nanoparticles
by: Saeideh Same, et al.
Published: (2016-09-01)

A first-in-human study investigating biodistribution, safety and recommended dose of a new radiolabeled MAb targeting FZD10 in metastatic synovial sarcoma patients
by: Anne-Laure Giraudet, et al.
Published: (2018-06-01)

EGFR Protein Expression in KRAS Wild-Type Metastatic Colorectal Cancer Is Another Negative Predictive Factor of the Cetuximab Therapy
by: Andrea Uhlyarik, et al.
Published: (2020-03-01)

Phase I Study of Ficlatuzumab and Cetuximab in Cetuximab-Resistant, Recurrent/Metastatic Head and Neck Cancer
by: Julie E. Bauman, et al.
Published: (2020-06-01)

Transgenic goats producing an improved version of cetuximab in milk
by: Götz Laible, et al.
Published: (2020-11-01)

Recent Trends in Bioorthogonal Click-Radiolabeling Reactions Using Fluorine-18
by: Doreen Pietzsch, et al.
Published: (2013-07-01)

RANKL/RANK pathway abrogates cetuximab sensitivity in gastric cancer cells via activation of EGFR and c-Src
by: Zhang X, et al.
Published: (2017-01-01)

Labeling of DOTA-conjugated HPMA-based polymers with trivalent metallic radionuclides for molecular imaging
by: Elisabeth Eppard, et al.
Published: (2018-02-01)

Epidermal growth factor receptor (EGFR) mutation status and Rad51 determine the response of glioblastoma (GBM) to multimodality therapy with cetuximab, temozolomide and radiation
by: Phyllis Rachelle Wachsberger, et al.
Published: (2013-02-01)

Ligand-Independent EGFR Activation by Anchorage-Stimulated Src Promotes Cancer Cell Proliferation and Cetuximab Resistance via ErbB3 Phosphorylation
by: Masami Nozaki, et al.
Published: (2019-10-01)

Study of EGFR expression in tumor tissue in patients with locally advanced oral cavity cancer receiving cetuximab therapy
by: A. A. Lyanova, et al.
Published: (2020-07-01)

Cetuximab-Induced MET Activation Acts as a Novel Resistance Mechanism in Colon Cancer Cells
by: Na Song, et al.
Published: (2014-04-01)

Dermopathy associated with cetuximab and panitumumab: investigation of the usefulness of moisturizers in its management
by: Watanabe S, et al.
Published: (2017-09-01)

Radiolabelled Aptamers for Theranostic Treatment of Cancer
by: Umair Khalid, et al.
Published: (2018-12-01)

The Dual Cell Cycle Kinase Inhibitor JNJ-7706621 Reverses Resistance to CD37-Targeted Radioimmunotherapy in Activated B Cell Like Diffuse Large B Cell Lymphoma Cell Lines
by: Gro Elise Rødland, et al.
Published: (2019-11-01)

Potential for Nuclear Medicine Therapy for Glioblastoma Treatment
by: Clément Bailly, et al.
Published: (2019-07-01)

EGFR targeting of [177Lu] gold nanoparticles to colorectal and breast tumour cells: Affinity, duration of binding and growth inhibition of Cetuximab-resistant cells
by: Rekaya Shabbir, et al.
Published: (2021-10-01)

Radiolabeling of Human Serum Albumin With Terbium-161 Using Mild Conditions and Evaluation of in vivo Stability
by: Irwin Cassells, et al.
Published: (2021-08-01)

Avaluació preclínica de l'efecte antitumoral de cetuximab sobre la malaltia microscòpica residual post-radioteràpia
by: Pueyo Castells, Gemma
Published: (2010)

Prediction of response to anti-EGFR antibodies in metastatic colorectal cancer: looking beyond EGFR inhibition.
by: Alessandro eOttaiano, et al.
Published: (2013-01-01)

Pharmacogenetic profiling and cetuximab outcome in patients with advanced colorectal cancer
by: Dahan Laetitia, et al.
Published: (2011-11-01)

Anti-EGFR therapies in nasopharyngeal carcinoma
by: Xishan Chen, et al.
Published: (2020-11-01)

Efficacy of Cetuximab in Combination with FOLFIRI in a Patient with KRAS Wild-Type Metastatic Anal Cancer
by: Hanna Barmettler, et al.
Published: (2012-08-01)

Interleukin-1 alpha increases anti-tumor efficacy of cetuximab in head and neck squamous cell carcinoma
by: Madelyn Espinosa-Cotton, et al.
Published: (2019-03-01)

Different responses of colorectal cancer cells to alternative sequences of cetuximab and oxaliplatin
by: Elli Narvi, et al.
Published: (2018-11-01)

Sub‐10 nm Radiolabeled Barium Sulfate Nanoparticles as Carriers for Theranostic Applications and Targeted Alpha Therapy
by: Falco Reissig, et al.
Published: (2020-08-01)

Mechanisms of Cell Killing Response from Low Linear Energy Transfer (LET) Radiation Originating from 177Lu Radioimmunotherapy Targeting Disseminated Intraperitoneal Tumor Xenografts
by: Kwon Joong Yong, et al.
Published: (2016-05-01)

Efficacy of Panitumumab and Cetuximab in Patients with Colorectal Cancer Previously Treated with Bevacizumab; a Combined Analysis of Individual Patient Data from ASPECCT and WJOG6510G
by: Hiroya Taniguchi, et al.
Published: (2020-06-01)

Cetuximab produced from a goat mammary gland expression system is equally efficacious as innovator cetuximab in animal cancer models
by: Qian Wang, et al.
Published: (2020-12-01)

Randomized Phase II Study of Duligotuzumab (MEHD7945A) versus Cetuximab in Squamous Cell Carcinoma of the Head and Neck (MEGHAN Study)
by: Jérôme FAYETTE, et al.
Published: (2016-10-01)

Overcoming Intrinsic and Acquired Cetuximab Resistance in RAS Wild-Type Colorectal Cancer: An In Vitro Study on the Expression of HER Receptors and the Potential of Afatinib
by: Ines De Pauw, et al.
Published: (2019-01-01)

Cetuximab-modified CuS nanoparticles integrating near-infrared-II-responsive photothermal therapy and anti-vessel treatment
by: Li B, et al.
Published: (2018-11-01)

Application of <sup>212</sup>Pb for Targeted α-particle Therapy (TAT): Pre-clinical and Mechanistic Understanding through to Clinical Translation
by: Kwon Yong, et al.
Published: (2015-08-01)

Whole Transcriptome Analysis Identifies TNS4 as a Key Effector of Cetuximab and a Regulator of the Oncogenic Activity of KRAS Mutant Colorectal Cancer Cell Lines
by: Sujin Kim, et al.
Published: (2019-08-01)

T cell receptor richness in peripheral blood increases after cetuximab therapy and correlates with therapeutic response
by: Benjamin A. Kansy, et al.
Published: (2018-11-01)

Transfert des gènes p53 et pten par vectorisation non virale : effet pro-apoptotique et potentialisation de la réponse cellulaire au cétuximab
by: Bouali, Sanae
Published: (2008)

Radioimmunotherapy of Pancreatic Ductal Adenocarcinoma: A Review of the Current Status of Literature
by: Ashleigh Hull, et al.
Published: (2020-02-01)